跳至主要内容
临床试验/NCT00862628
NCT00862628Unknown不适用

The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries

Nagoya University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
The number of mucosal breaks

研究概览

简要总结

The purpose of this study is to evaluate the efficacy of rebamipide for NSAID-induced small-intestinal injuries.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • 20 to 85 years of age
  • RA, OA, or low back pain
  • No change of drugs before 3 months
  • Under 5 mg of corticosteroid use
  • CRP < 1mg/dl
  • Small-intestinal mucosal injuries more than one
  • Hemoglobin level is below normal range

排除标准

  • Known or suspected small-bowel disease, including Crohn's disease and seronegative arthritis
  • Prostaglandins, metronidazole or salazosulfapyridine
  • Can not swallow
  • Eith pacemaker
  • After gastrointestinal operation
  • Serious concomitant cardiovascular, endocrine, gastrointestinal(including symptoms of ileus), neurologic, psychiatric, renal, or respiratory disease.
  • Taking rebamipide before one week
  • Any other conditions that the investigator feels would interfere with data interpretation or create under risk.

研究组 & 干预措施

Rebamipide

Experimental

干预措施: Rebamipide (Drug)

结局指标

主要结局

The number of mucosal breaks

时间窗: 4 and 8 weeks after treatment

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验